Immuneel Therapeutics secures over Rs 100 Cr Series B funding

Immuneel Therapeutics secures over Rs 100 Cr Series B funding

Immuneel Therapeutics, a Bengaluru-based cell and gene therapy startup, has announced the successful close of its Rs 100 crore plus Series B financing. The round saw participation from new investors including Singularity AMC, Rainmatter by Zerodha, and several High-Net-Worth Individuals alongside strong continued support from existing investors including Kiran Mazumdar-Shaw, Eight Roads Ventures, and F-Prime Capital.

The financing will directly fund key strategic priorities: scaling Immuneel's GMP manufacturing capacity, advancing its next-generation deep-tech cell and gene therapy pipeline toward clinical milestones, supporting the commercialisation of Qartemi, and accelerating international market entry across Asia Pacific and Middle East.

Following the successful commercial launch of Qartemi, approved CAR-T therapy for Non-Hodgkin Lymphoma, Immuneel Therapeutics is now extending its reach into high growth emerging markets and progressing clinical co-development partnerships in Australia and Southeast Asia.

The company operates India's first international standard CAR-T platform to deliver world-class therapies at a fraction of the Western costs.

Amit Mookim, Chief Executive Officer of Immuneel Therapeutics, said "Qartemi’s commercialisation proved we can deliver world-class CAR-T outcomes at a fraction of Western costs. This Series B financing accelerates what comes next: a bold international expansion and a next-generation pipeline that will redefine how cell therapies reach patients globally."

Published on : 09th June, 2026